文章：

局部及局部进展期肾细胞癌新辅助治疗综述

A Review of Neoadjuvant Therapy for Localized and Locally Advanced Renal Cell Carcinoma

原文发布日期：19 January 2025

DOI: 10.3390/cancers17020312

类型: Article

开放获取: 是

英文摘要：

The introduction of vascular endothelial growth factor receptor-tyrosine kinases (VEGFR-TKIs) and immune checkpoint inhibitors (IOs) have drastically altered the treatment landscape for kidney cancer, with doublet combination immunotherapy (IO/IO or IO/VEGFR-TKI) now set as the standard front-line treatment for advanced renal cell carcinoma (RCC). However, the roles of VEGFR-TKIs and IOs in the neoadjuvant setting for locoregional/locally advanced RCC remain undefined, where the goals may be primary tumor downsizing/downstaging and potentially eradicating micrometastatic disease. This review will examine VEGFR-TKI monotherapy, IO monotherapy, and VEGFR-TKI/IO combination regimens in a preoperative setting with a focus on the efficacy, toxicity, surgical, and long-term implications.

摘要翻译： 

血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKIs）与免疫检查点抑制剂（IOs）的应用显著改变了肾癌的治疗格局，目前双药联合免疫疗法（IO/IO或IO/VEGFR-TKI）已成为晚期肾细胞癌（RCC）的标准一线治疗方案。然而，在局部/局部晚期肾细胞癌的新辅助治疗领域，VEGFR-TKIs与IOs的作用尚未明确，其治疗目标可能包括原发肿瘤减容/降期以及潜在清除微转移病灶。本综述将探讨术前应用VEGFR-TKI单药治疗、IO单药治疗及VEGFR-TKI/IO联合方案的疗效、毒性反应、手术相关影响及长期预后。

原文链接：

A Review of Neoadjuvant Therapy for Localized and Locally Advanced Renal Cell Carcinoma